BS006 is another HSV-2-based engineered oncolytic virus designed to express a PD-L1/CD3 bispecific antibody-like molecule within a tumor, currently undergoing phase I testing in melanoma and other advanced solid tumors [46,50]. This evidence concerns the gene CD274 and neoplasm.